ANP32E expression in pancreatic cancer is associated with impaired gemcitabine efficacy and poor patient prognosis

Xiaohong Liu; Yelin Zhao; Li Zhang; Junting Wang; Liaoxin Luo; Shihui Zhang; Qin Zhu; Yuchen Shi; Chenyu Yuan; Qifeng Xiao; Mengran Xiong; Yuanyuan Duan; Hebing Chen; Hongjuan Yao; Lin Cai; Jianwei Zhang; Guangxi Li; Liang Li

doi:10.1016/j.mcp.2025.102030

Molecular and Cellular Probes (Aug 2025)

ANP32E expression in pancreatic cancer is associated with impaired gemcitabine efficacy and poor patient prognosis

Xiaohong Liu,
Yelin Zhao,
Li Zhang,
Junting Wang,
Liaoxin Luo,
Shihui Zhang,
Qin Zhu,
Yuchen Shi,
Chenyu Yuan,
Qifeng Xiao,
Mengran Xiong,
Yuanyuan Duan,
Hebing Chen,
Hongjuan Yao,
Lin Cai,
Jianwei Zhang,
Guangxi Li,
Liang Li

Affiliations

Xiaohong Liu: State Key Laboratory of Respiratory Health and Multimorbidity, NHC Key Laboratory of Biotechnology for Microbial Drugs, Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, NO.1 Tiantan Xili, Beijing, 100050, China; Qilu Hospital of Shandong University, Jinan, 250012, Shandong Province, China; Guang'anmen Hospital, Chinese Academy of Chinese Medical Sciences, Beijing, 100053, China
Yelin Zhao: State Key Laboratory of Respiratory Health and Multimorbidity, NHC Key Laboratory of Biotechnology for Microbial Drugs, Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, NO.1 Tiantan Xili, Beijing, 100050, China
Li Zhang: State Key Laboratory of Respiratory Health and Multimorbidity, NHC Key Laboratory of Biotechnology for Microbial Drugs, Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, NO.1 Tiantan Xili, Beijing, 100050, China
Junting Wang: Institute of Health Service and Transfusion Medicine, Beijing, 100850, China
Liaoxin Luo: Department of Biopharmaceuticals, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang Province, China
Shihui Zhang: Department of Biopharmaceuticals, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang Province, China
Qin Zhu: Department of Biopharmaceuticals, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang Province, China
Yuchen Shi: Dongzhimen Hospital, Beijing University of Chinese Medicine, No.5 Haiyuncang, Beijing, 100700, China
Chenyu Yuan: State Key Laboratory of Respiratory Health and Multimorbidity, NHC Key Laboratory of Biotechnology for Microbial Drugs, Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, NO.1 Tiantan Xili, Beijing, 100050, China
Qifeng Xiao: Pancreatic and Gastric Surgery Department, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
Mengran Xiong: Guang'anmen Hospital, Chinese Academy of Chinese Medical Sciences, Beijing, 100053, China
Yuanyuan Duan: Guang'anmen Hospital, Chinese Academy of Chinese Medical Sciences, Beijing, 100053, China
Hebing Chen: Institute of Health Service and Transfusion Medicine, Beijing, 100850, China
Hongjuan Yao: State Key Laboratory of Respiratory Health and Multimorbidity, NHC Key Laboratory of Biotechnology for Microbial Drugs, Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, NO.1 Tiantan Xili, Beijing, 100050, China
Lin Cai: Department of Biopharmaceuticals, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang Province, China; Co-corresponding authors.
Jianwei Zhang: Pancreatic and Gastric Surgery Department, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China; Co-corresponding authors. Pancreatic and Gastric Surgery Department, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Guangxi Li: Guang'anmen Hospital, Chinese Academy of Chinese Medical Sciences, Beijing, 100053, China; Co-corresponding authors. Guang'anmen Hospital, Chinese Academy of Chinese Medical Sciences, No.5 BeiXianGe St., Beijing 100053, China
Liang Li: State Key Laboratory of Respiratory Health and Multimorbidity, NHC Key Laboratory of Biotechnology for Microbial Drugs, Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, NO.1 Tiantan Xili, Beijing, 100050, China; Co-corresponding authors. State Key Laboratory of Respiratory Health and Multimorbidity, NHC Key Laboratory of Antibiotic Bioengineering of National Health and Family Planning Commission, Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, NO.1 Tiantan Xili, Beijing, 100050, China.

DOI: https://doi.org/10.1016/j.mcp.2025.102030
Journal volume & issue: Vol. 82
p. 102030

Abstract

Read online

Purpose: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive and fatal malignancy, although gemcitabine is administered as a single or combined therapeutic agent. Our previous study demonstrated that ANP32E overexpression promoted PDAC cell proliferation. However, whether it affects treatment outcome and clinical prognosis is still unclear. In the present study, we aimed to determine whether ANP32E is negatively associated with the treatment outcome of gemcitabine. Methods: We collected clinical characteristics and treatment information from a total of 75 PDAC patients to assess the association of ANP32E expression via immunohistochemical (IHC) staining with overall survival (OS) in patients who were or were not treated with gemcitabine-based chemotherapy, followed by a clinical replication study with transcriptomic data from the TCGA database and functional validation experiments involving the knockdown of ANP32E in the Hup-T3 and SU86.86 human pancreatic cancer cell lines. Results: We demonstrated the interference effect of ANP32E on gemcitabine efficacy and patient prognosis in PDAC patients by using our own clinical samples or publicly available TCGA datasets. Downregulation of ANP32E significantly sensitized Hup-T3 and SU86.86 cells to gemcitabine, which was consistent with the results of the above association studies. Conclusion: Our findings suggest that ANP32E might serve as a negative biomarker for poor prognosis and a predictive indicator for poor gemcitabine efficacy. These findings suggest that ANP32E might be a potential therapeutic target to help develop effective drugs to overcome gemcitabine resistance and reduce the risk for relapse or metastasis in patients with PDAC.

Published in Molecular and Cellular Probes

ISSN: 0890-8508 (Print); 1096-1194 (Online)
Publisher: Elsevier
Country of publisher: United Kingdom
LCC subjects: Science: Biology (General); Medicine
Website: https://www.sciencedirect.com/journal/molecular-and-cellular-probes

About the journal

Abstract

Keywords